

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine months ended September 30, 2023 and 2022

Expressed in Canadian dollars

NOTICE OF NO AUDIT OR REVIEW OF INTERIM FINANCIAL STATEMENTS

The accompanying unaudited interim financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

Condensed consolidated interim statements of profit or loss and comprehensive income or loss - unaudited $\,$

(Expressed in Canadian dollars)

		Three months ended	September 30,	Nine months ended September 30,		
	Note	2023	2022	2023	2022	
		\$000s	\$000s	\$000s	\$000	
Operating expenses						
Accounting, legal and professional		(220)	(174)	(600)	(560	
Depreciation	6	(11)	(11)	(34)	(34	
Office and general		(37)	(44)	(149)	(157	
Salaries, director and consultant fees		(228)	(226)	(672)	(705	
Share-based payments recovery/(expense)		(83)	337	346	426	
Social responsibility and other project related costs		(317)	(22)	(386)	(68	
Gain/(loss) on foreign exchange		(691)	(2,382)	12	(3,577	
Operating loss		(1,587)	(2,522)	(1,483)	(4,675	
Finance expense	6	(825)	(764)	(2,427)	(2,278	
Fair value gain/(loss) on financial liabilities	9 (b)	(2)	247	6	254	
Net finance loss	•	(827)	(517)	(2,421)	(2,024	
Loss for the period		(2,414)	(3,039)	(3,904)	(6,699	
Other comprehensive loss, net of tax:						
Items that are or may be reclassified subsequently to profit o	r loss					
Translation adjustment on foreign subsidiaries		(202)	(264)	(220)	(1,657	
Total other comprehensive loss, net of tax		(202)	(264)	(220)	(1,657	
Total comprehensive loss for the period		(2,616)	(3,303)	(4,124)	(8,356	
Loss per common share						
Basic and diluted	5	(0.01)	(0.01)	(0.01)	(0.02	
Weighted average number of common shares outstanding						

 $Condensed\ consolidated\ interim\ statements\ of\ financial\ position\ -\ unaudited$

(Expressed in Canadian dollars)

		As at	
		September 30,	December 31,
	Note	2023	2022
		\$000s	\$000s
ASSETS			
Current			
Cash and cash equivalents		1,452	24
Other receivables		97	67
Other current assets		39	92
Total current assets		1,588	183
Non-current assets			
Land and property, plant and equipment		163	198
Mineral right interests	7	37,176	37,483
Total assets	-	38,927	37,864
LIABILITIES			
Current			
Trade and other payables		311	860
• •	10	15,188	15,236
Gold purchase advance payments		•	,
Share-based payment liabilities	11 (c) 9	2,191	2,749
Loans and borrowings	9	27,135	27,810
Lease liability		52	52
Total current liabilities		44,877	46,707
Non-current liabilities			
Lease liability		56	89
Total liabilities		44,933	46,796
EQUITY			
Share capital	8	82,132	78,899
Equity reserve		18,311	15,828
Convertible loan reserve	9 (b)	1,334	1,245
Currency translation reserve		2,948	3,168
Accumulated losses		(110,731)	(108,072
Total deficit		(6,006)	(8,932
Total liabilities and equity		38,927	37,864
Nature of operations	1		
Subsequent events	13		
Approved on behalf of the Board of Directors			
Signed "Tim Morgan-Wynne"			
Tim Morgan-Wynne, Director			

Condensed consolidated interim statements of changes in equity - unaudited

(Expressed in Canadian dollars)

For the nine months ended September 30, 2023 and 2022								
		Share capital		Equity	Convertible	Currency translation	Accumulated	Total
	Note	Number of shares	Amount		loan reserve	reserve	losses	equity
	Note	Number of shares	\$000s	reserve \$000s	\$000s	\$000s	\$000s	\$000s
			\$000\$	\$0008	\$000S	\$0005	\$000\$	\$0008
Balance on January 1, 2022		352,906,200	78,796	15,962	1,162	3,402	(101,365)	(2,043)
Total comprehensive loss for the period								
Loss for the period			-	-	-	-	(6,699)	(6,699)
Other comprehensive loss for the period			-	-	-	(1,657)	-	(1,657)
Total comprehensive loss for the period			-	-	-	(1,657)	(6,699)	(8,356)
Transactions with owners of the Company								
Exercised equity-settled share-based payments	8	515,000	103	(103)	-	-	-	-
Equity-settled share-based payments			-	24	-	-	-	24
Derecognition of the equity component of convertible loan	9 (b)		-	-	(1,162)	-	1,162	-
Equity component of convertible loan	9 (b)		-	-	1,245	-	· -	1,245
Total transactions with owners of the Company			103	(79)	83	-	1,162	1,269
Balance on September 30, 2022		353,421,200	78,899	15,883	1,245	1,745	(106,902)	(9,130)
Balance on January 1, 2023		353,421,200	78,899	15,828	1,245	3,168	(108,072)	(8,932)
Total comprehensive loss for the period								
Loss for the period			_	_	_	_	(3,904)	(3,904)
Other comprehensive loss for the period			_	_	_	(220)	(3,304)	(220)
Total comprehensive loss for the period			-	-	-	(220)	(3,904)	(4,124)
Transactions with owners of the Company								
Common shares issued, net of issue costs	8	101,250,000	1,595	2,270	-	-	-	3,865
Conversion of the convertible notes	8	35,342,120	1,638	-,	-	-	_	1,638
Equity-settled share-based payments	-	,	-,	213	-	-	-	213
Derecognition of the equity component of convertible loan	9 (b)		-		(1,245)	-	1,245	-
Equity component of convertible loan	9 (b)		-	-	1,334	-	-,	1,334
Total transactions with owners of the Company	- (~)		3,233	2,483	89	-	1,245	7,050
Balance on September 30, 2023		490,013,320	82,132	18,311	1,334	2,948	(110,731)	(6,006)

Condensed consolidated interim statements of cash flows - unaudited (Expressed in Canadian dollars)

		Nine months ended S	September 30,
		2023	2022
	Note	\$000s	\$000s
OPERATING ACTIVITIES			
Loss before tax		(3,904)	(6,699)
Add back:			
Depreciation	6	34	34
Finance expense	6	2,427	2,278
Share-based payments recovery		(346)	(426)
Unrealised foreign exchange loss		4	3,564
Expensed transaction costs associated with convertible loans	9 (b)	67	77
Expensed transaction costs associated with promissory note	9 (b)	-	54
Fair value gain on financial liabilities	9 (b)	(6)	(254)
Changes in non-cash working capital items:			
Increase in other receivables and other current assets		(34)	(4)
(Decrease)/increase in trade and other payables		(506)	45
Cash used in operating activities		(2,264)	(1,331)
FINANCING ACTIVITIES			
Proceeds from shares issued	8	4,015	-
Proceeds from convertible notes	9 (a)	· <u>-</u>	1,284
Share issue costs	8	(113)	-
Transaction costs associated with convertible loans	9 (b)	(134)	(141)
Transaction costs associated with convertible notes	9 (b)	(19)	(54)
Payment of lease liabilites		(39)	(37)
Interest paid		(5)	(4)
Cash provided in financing activities		3,705	1,048
Effect of exchange rate changes on cash		(13)	28
Net change in cash and cash equivalents		1,441	(283)
Cash and cash equivalents, beginning of the period		24	338
Cash and cash equivalents, end of the period		1,452	83

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

1. Nature of operations

Euromax Resources Ltd. ("Euromax" or the "Company") was incorporated under the Business Corporation Act ("British Columbia") and established as a legal entity on May 1, 1990. The registered address of the Company is located at 700 West Georgia St, Suite 2200, Vancouver, British Columbia, Canada V7Y 1K8.

These condensed consolidated interim financial statements include the accounts of Euromax and of its wholly-owned subsidiaries (collectively, the "Group"). The Group operates with the objective of becoming the leading gold and base metal mining company in Europe. The Group operates in one sector in the mining industry, i.e. the exploration and development of mineral right interests.

Euromax's common shares are listed on the Toronto Stock Exchange (the "TSX") under the trading symbol "EOX", however following a remedial delisting review Euromax has applied to list its securities on the TSX Venture Exchange (the "TSXV"). As at the date of authorisation of these condensed consolidated interim financial statements, this process for transferring the listing of the Euromax's common shares to TSXV is still ongoing. Euromax's common shares are also listed on the OTC Pink Market under the trading symbol "EOXFF". Euromax's share options and warrants are not listed.

These condensed consolidated interim financial statements were authorised for issue by the Company's board of directors on November 3, 2023.

2. Basis of preparation and statement of compliance

These condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") applicable to the preparation of interim financial statements, including International Accounting Standard ("IAS") 34 Interim Financial Reporting. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2022, which were prepared in accordance with IFRS as issued by the IASB.

The Group has applied the same accounting policies and methods of computation in these condensed consolidated interim financial statements as it did in the audited consolidated financial statements for the year ended December 31, 2022.

3. Going concern

These condensed consolidated interim financial statements have been prepared on a going concern basis which assumes the continuity of normal business activity and the realisation of assets and settlement of liabilities in the normal course of business.

At September 30, 2023, the Group had net liabilities of \$6 million (December 31, 2022: \$8.9 million) and a net working capital deficiency of \$43.3 million (December 31, 2022: \$46.5 million), including cash of \$1.5 million (December 31, 2022: \$0.024 million). The Group's \$43.3 million working capital deficiency at September 30, 2023 largely results from:

- Convertible loans of \$27.1 million (at December 31, 2022: \$26.2 million) with European Bank for Reconstruction and Development ("EBRD") (the "EBRD convertible loan") and with CC llovitza ("CCI" a member of the CCC Group) (the "CCI convertible loan"), both mature on February 28, 2024 and therefore classified as current liabilities (see Note 9); and
- Gold purchase advance payments of \$15.2 million (December 31, 2022: \$15.2 million) received from Royal Gold, AG ("Royal Gold") (see Note 10) which are repayable within 60 days of receiving a termination notice to the Gold Purchase and Sale Agreement.

These two items are classified as current liabilities as at this time contractual repayment may be required within the next twelve months. Both convertible loans are convertible into the Company's common shares at the election of EBRD and CCI on or before their maturity (see Note 9 for more details). As at the date of these condensed consolidated interim financial statements no termination or repayment notice has been received from Royal Gold.

On January 24, 2023 the Group closed a non-brokered private placement (the "2023 Private Placement") for gross proceeds of US\$3 million or \$4.015 million, and following that, both convertible notes of US\$1.25 million, issued in the year ended December 31, 2022, were converted into Company's common shares on January 26, 2023 (see Note 8).

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

3. Going concern (continued)

The Company's board of directors has reviewed the Group's forecasts for the period ended December 31, 2024, in which are included all committed costs for maintaining the Ilovica-Shtuka copper project (the "Ilovica-Shtuka Project") in the Republic of North Macedonia ("Macedonia" or the "Country"), and are prepared based on the following major assumptions:

- the convertible loans which have potential contractual cash outflows at February 28, 2024 of \$28.5 million will either be converted into the Company's common shares or further extended to mature beyond the forecast period; and
- neither termination nor repayment notices will be received from Royal Gold for the period ended December 31, 2024.

Based on these forecasts, the directors have identified that further funding will be required to:

- cover the committed costs for maintaining the Ilovica-Shtuka Project from April 2024 and going
 forward, including covering the local legal costs for the ongoing and potential administrative
 processes until the final approval of the request for the merger of the Group's two exploitation
 concessions (the "Merger");
- repay the gold purchase advance payments, if termination or repayment notice is received from Royal Gold;
- repay both convertible loans, if neither are further extended in 2024 or converted into the Company's common shares; and
- ultimately construct and bring the Ilovica-Shtuka Project into commercial production.

The directors note that the level of funding required is dependent on both the outcome and duration of the administrative process for getting approval of the Merger.

Given the above factors, the Group will need to raise additional funds from April 2024 either through equity (supported by existing shareholders or new shareholders) or by further debt.

These events are outside of the Group's control, and as such, a material uncertainty exists which may cast significant doubt about the Group's continued ability to operate as a going concern and its ability to realise its assets and discharge its liabilities in the normal course of business.

These condensed consolidated interim financial statements do not include any adjustments that may result from the outcome of these uncertainties.

4. Critical accounting judgements and key sources of estimation uncertainty

The preparation of these condensed consolidated interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these judgements and estimates. In preparing these condensed consolidated interim financial statements, the significant judgements and estimates made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the audited consolidated financial statements for the year ended December 31, 2022.

These condensed consolidated interim financial statements have been prepared on a going concern basis which assumes the continuity of normal business activity and the realisation of assets and settlement of liabilities in the normal course of business.

5. Loss per share

	Thurs we such a surder	d Ctb 20	Nine mention and a	C
	Inree months ended	a September 30,	Nine months ended	September 30,
	2023	2022	2023	2022
			\$000s	\$000s
Net loss for the period after tax	(2,414)	(3,039)	(3,904)	(6,699
Basic weighted average number of common shares	490,013,320	353,421,200	477,746,305	353,374,039
Basic and diluted loss per share	(0.01)	(0.01)	(0.01)	(0.02

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

5. Loss per share (continued)

For the three and nine months ended September 30, 2023 and 2022, because there would be further reduction in loss per share resulting from the assumption that share options, share purchase warrants and convertible loans are exercised or converted, all these instruments are considered as anti-dilutive and are ignored in the computation of loss per share. As there were no other instruments that may have a potential dilutive impact, the basic and diluted loss per share were the same for the three and nine months ended September 30, 2023 and 2022.

6. Operating segments

The Group's principal business is the exploration and development of mineral right interests. The Group's board of directors (the Group's Chief Operating Decision Maker) has arranged the Group's operating segments by both type of business and by geographic region. No operating segments have been aggregated in arriving at the reportable segments of the Group.

The Group's reportable segments are as follows:

Reportable segments	Operations	Geografic location
Macedonia	exploration and development of mineral right interests	Republic of North Macedonia
Corporate	corporate operations	Canada and UK

The following is an analysis of the Group's profit or loss before tax, assets and liabilities by operating segments and the Group's consolidated loss before tax.

	Macedonia		Corpo	orate	Total		
Nine months ended	September 30,						
In thousands \$	2023	2022	2023	2022	2023	2022	
Finance expense	(8)	(7)	(2,419)	(2,271)	(2,427)	(2,278)	
Depreciation	(34)	(34)	-	-	(34)	(34)	
Loss for the period	(916)	(3,233)	(2,988)	(3,466)	(3,904)	(6,699)	

	Mace	Macedonia		orate	Total		
As at	September 30,	December 31,	September 30,	December 31,	September 30,	December 31,	
In thousands \$	2023	2022	2023	2022	2023	2022	
Assets	37,539	37,764	1,388	100	38,927	37,864	
Liabilities	266	328	44,667	46,468	44,933	46,796	

7. Mineral right interests

Macedonia

On July 11, 2007 the Group acquired an option to earn a 100% interest in the Ilovica-Shtuka Project. After completing an agreed exploration programme and the vendor not exercising its back-in right in January 2012, the Group acquired a 100% interest in the Ilovica-Shtuka Project.

The Ilovica-Shtuka Project consists of two adjacent properties, exploitation concessions Ilovica 6 and Ilovica 11. Under the rules and regulations of the Minerals Law in Macedonia, the exploitation concession for Ilovica 6 was granted on July 24, 2012, while the exploitation concession for Ilovica 11 granted on January 13, 2016. Both exploitation concessions have an initial term of 30 years and subject to a state royalty of 2% of the market value of metals contained in concentrate.

On January 6, 2016 the Group announced the Feasibility Study (the "FS") for the Ilovica-Shtuka Project, prepared in compliance with National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101"), while during 2017 the Environmental and Social Impact Assessment Study (the "ESIA") was completed under international standards, which could facilitate the financing of the Ilovica-Shtuka Project's construction as well as meets the requirements of various project stakeholders.

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

7. Mineral right interests (continued)

Macedonia (continued)

During 2017 and 2018, the Ministry of Economy (the "MoE") positively responded on the request for the merger of both exploitation concessions llovica 6 and llovica 11 (or the Merger), submitted in January 2016. Following the positive decisions of the administrative courts that annulled the termination of the exploitation concession on llovica 6 on the basis that the Merger represents an administrative preliminary matter, the final approval for the Merger was granted on June 27, 2023, by the Government of the Republic of North Macedonia, as announced on July 4, 2023 in the Official Gazette. However, on July 25, 2023, the Government reversed this decision and annulled the Merger approval, as announced on July 26, 2023 in the Official Gazette. The Group filed a lawsuit against this subsequent Government decision which was made without any legal basis and will resubmit its application for the Merger at the appropriate time. Until this is resolved, the Group remains in the process of waiting for the Merger approval by the Government.

During 2017, a Strategic Environmental Impact Assessment was approved by the MoEPP (required for urbanisation process of the mine footprint), and a commission within the MoEPP issued a Compliance Report for the Environmental Impact Assessment Study (the "EIA") and recommended a formal approval to be granted by the MoEPP. However, the final approval of the EIA has not been granted at the date of these consolidated financial statements.

The option for recovering the investment and potential damages from the Ilovica-Shtuka Project by initiating an international arbitration under the arbitration rules of the International Centre of the Settlement of Investment Disputes ("ICSID") in Washington D.C., USA will remain as available alternative for the Group in case of valuation of the bilateral agreement between Republic of North Macedonia and the Swiss Federal Council for protection of investments.

Based on independent legal advice and the latest positive developments for the Ilovica-Shtuka Project, at September 30, 2023 the Group is of the view that there is no need for impairment of the carrying amount of the mineral right interest for the Ilovica-Shtuka Project as presented below.

A summary of changes to the Group's mineral right interests in the nine months ended September 30, 2023 and 2022 is set out below.

	Macedonia
	Ilovica-Shtuka Project
	\$000s
Balance, January 1, 2022	37,499
Other items:	
Exchange differences	(2,989)
Balance, September 30, 2022	34,510
Balance, January 1, 2023 Other items:	37,483
Exchange differences	(307)
Balance, September 30, 2023	37,176

8. Share capital and reserves

At September 30, 2023 Euromax's authorised share capital consisted of an unlimited number of common shares without par value. All issued common shares are fully paid.

	2023		202	2
	Number		Number	
	of shares	of shares	Amount	
		\$000s		\$000s
Balance on January 1	353,421,200	78,899	352,906,200	78,796
Common shares issued, net of issue costs	101,250,000	1,595	-	-
Conversion of the convertible notes	35,342,120	1,638	-	-
Exercised equity-settled share-based payments		-	515,000	103
Balance on September 30	490,013,320	82,132	353,421,200	78,899

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

8. Share capital and reserves (continued)

On January 24, 2023 the Company announced closing of the 2023 Private Placement for gross proceeds of US\$3 million or \$4.015 million for issuing 101,250,000 common shares and 101,250,000 share purchase warrants. These issued 101,250,000 share purchase warrants have the following vesting conditions: 50,625,000 share purchase warrants vest on approval of the Merger (defined as "A Warrants"), while the other 50,625,000 share purchase warrants vest on approval of the Exploitation Permit on the merged concession for the Ilovica-Shtuka Project and approval of the Environmental Impact Assessment on the merged concession for the Ilovica-Shtuka Project (defined as "B Warrants"). All these 101,250,000 share purchase warrants are exercisable for a period of two years from the date of issuance, whereby A Warrants are exercisable at a price of \$0.075, and B Warrants at price of \$0.125.

The aggregate fair market value of the share purchase warrants and the common shares issued in the 2023 Private Placement was distributed on a pro-rata basis between share capital and equity reserve. The fair value of the share purchase warrants was estimated at \$0.02655 for A Warrant and \$0.02003 for B Warrant, or in total of \$2.358 million for all issued 101,250,000 share purchase warrants, at the grant date by using the Black-Scholes option pricing model.

The Company incurred share issue costs of \$0.150 million for filing and legal fees, of which \$0.037 million were paid at December 31, 2022, while \$0.113 million were paid during the nine months ended September 30, 2023. These share issue costs of \$0.150 million were allocated on a proportional basis, whereby \$0.062 million were allocated to share capital while \$0.088 million to share purchase warrants via the equity reserve.

Following closing of the 2023 Private Placement, on January 26, 2023 both convertible notes (see Note 9) of \$1.638 million or US\$1.25 million, issued in the year ended December 31, 2022, were converted into 35,342,120 common shares.

During the nine months ended September 30, 2022, fully vested 515,000 restricted share units ("RSUs"), granted to key management personnel, were converted into common shares.

During the nine months ended September 30, 2023 and 2022, no share options and no share purchase warrants were exercised.

At September 30, 2023, the Company had 8,378,603 share options outstanding (September 30, 2022: 8,728,603) with exercise prices ranging from \$0.03 to \$0.08 per share and a weighted average exercise price of \$0.05.

During the nine months ended September 30, 2023, the Group granted 6,250,000 RSUs for its consultant, whereby 3,125,000 RSUs vest on approval of the Merger and EIA and 3,125,000 RSUs on approval of the Exploitation Permit on the new merged concession. While in the nine months ended September 30, 2022, 320,000 RSUs were granted to a senior officer of the Group.

The Company had 122,226,678 share purchase warrants (September 30, 2022: 20,976,678) with weighted average exercise price of \$0.10 per common share and 8,546,155 RSUs (September 30, 2022: 2,296,155) outstanding at September 30, 2023.

9. Loans and borrowings

	September 30,	December 31,
	2023	2022
	\$000s	\$000s
EBRD convertible loan	15,562	14,841
CCI convertible Ioan	11,573	11,331
Convertible notes	-	1,638
	27,135	27,810

(a) Terms and conditions

The terms and conditions of outstanding loans are as follows:

				September	30, 2023	2023 December 31, 20		
	Currency	Nominal interest rate	Year of maturity	Face value	Carrying amount	Face value	Carrying amount	
		meerestrate	mucuncy	\$000s	\$000s	\$000s	\$000s	
EBRD convertible loan	US\$	7.00%	2024	6,750	15,562	6,772	14,841	
CCI convertible loan	\$	7.00%	2024	5,200	11,573	5,200	11,331	
Convertible notes	US\$	interest fee	2023	-	-	1,693	1,638	
				11,950	27,135	13,665	27,810	

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

9. Loans and borrowings (continued)

(a) Terms and conditions (continued)

EBRD convertible loan

On May 24, 2016 the Company closed the EBRD convertible loan with EBRD and received proceeds of US\$5 million (\$6.750 million) (the "Principal Amount"), amended in April 2018, March 2019, February 2021, February 2022 (the "2022 Amendments of the EBRD convertible loan") and February 2023 (the "2023 Amendments of the EBRD convertible loan").

The EBRD convertible loan matures on February 28, 2024, extended from February 28, 2023 as per the 2023 Amendments of the EBRD convertible loan.

Upon maturity, the Company will be required to pay or convert:

- the Principal Amount,
- an amount of US\$1.420 million (\$1.917 million) (the "Redemption Amount"),
- a finance delay fee of US\$0.150 million (\$0.203 million) (the "Fee"),
- finance delay interest (the "Interest") accrued from January 1, 2017 until April 30, 2018 on the Principal Amount at the rate of 3 months LIBOR plus 7% per annum, compounded quarterly, and
- finance interest (the "Interest on Extension") accrued from May 1, 2018 to its maturity on collectively
 the Principle Amount, the Redemption Amount, the Fee and the Interest at April 30, 2018 at a rate of
 20% per annum applied from May 1, 2018 to March 31, 2019 and 7% per annum from April 1, 2019
 to its maturity, compounded annually.

The EBRD convertible loan is convertible into the Company's common shares, in whole or in part at the election of EBRD, at strike price of \$0.15 per common share for conversion of all the Principal Amount, the Redemption Amount, the Fee, the Interest, and the Interest on Extension.

CCI convertible loan

On May 20, 2016 the Company closed a convertible loan with CCI and received proceeds of \$5.2 million, amended in April 2018, March 2019, February 2021, February 2022 (the "2022 Amendments of the CCI convertible loan") and February 2023 (the "2023 Amendments of the CCI convertible loan").

The CCI convertible loan matures on February 28, 2024, extended from February 28, 2023 as per the 2023 Amendments of the CCI convertible loan.

The CCI convertible loan incurred a fixed interest rate of 20% per annum, compounded annually (changed from interest rate of 9% per annum, compounded daily), applied retrospectively from May 20, 2016 to March 31, 2019, repayable at maturity, while from April 1, 2019 until its maturity incurs fixed interest rate of 7% per annum, compounded annually.

At maturity, CCI can elect to receive cash repayment or convert the outstanding loan balance into the Company's common shares at a conversion price of \$0.15 per common share.

Convertible notes

During the year ended December 31, 2022, the Group received US\$1.25 million (\$1.627 million) under two non-interest bearing, unsecured, convertible notes issued to its major shareholder, as a bridge finance for covering short-term working capital until closing of the 2023 Private Placement.

The first convertible note of US\$1 million was issued on July 11, 2022, for US\$0.5 million (\$0.637 million) received on February 24, 2022 and US\$0.5 million (\$0.647 million) received on July 11, 2022. This first convertible note is convertible into the Company's common shares at strike price of \$0.0525 per common share for conversion of the principal amount and by using fixed foreign exchange rate, whereby US\$1 should be converted into \$1.3, up to 24,761,904 common shares would be issued from conversion of this convertible note.

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

9. Loans and borrowings (continued)

(a) Terms and conditions (continued)

Convertible notes (continued)

The second convertible note of US\$0.25 million was issued on October 18, 2022 for US\$0.25 million (\$0.343 million) received on October 17, 2022. This second convertible note is convertible into the Company's common shares at strike price of \$0.032 per common share for conversion of the principal amount and by using fixed foreign exchange rate, whereby US\$1 should be converted into \$1.35, up to 10,580,216 common shares would be issued from conversion of this convertible note.

Following closing of the 2023 Private Placement (see Note 8), on January 26, 2023 both convertible notes of \$1.638 million or US\$1.25 million were converted into 35,342,120 common shares.

(b) Recognition and measurement of convertible loans

EBRD convertible loan

EBRD convertible loan	2023	2022
	\$000s	\$000s
Carrying amount at January 1	14,841	13,087
Adjustments recorded during the period:		
Accrued interest	772	688
Fair value adjustment	(6)	(152)
Foreign exchange movements	(45)	1,125
Carrying amount at September 30	15,562	14,748

The EBRD convertible loan is designated as fair value through profit or loss ("FVTPL"), whereby all attributable transaction costs, together with any accrued interest, foreign exchange movements and fair value adjustments are recognised in profit or loss.

During the nine months ended September 30, 2023 transaction costs of \$0.067 million were incurred for the 2023 Amendments of the EBRD convertible loan (2022: \$0.077 million incurred for the 2022 Amendments of the EBRD convertible loan).

As per provisions of IFRS 9 Financial Instruments, the amount of change in the fair value of financial liability designated as FVTPL attributable to change in the credit risk of that liability shall be presented in other comprehensive income or loss, while the remaining amount of change in the fair value of the liability shall be presented in profit or loss. Based on the management estimate, the effect of fair value movement of the EBRD convertible loan resulting from changes in the credit risks of the EBRD convertible loan do not have material effect on the Group's condensed consolidated interim financial statements, and therefore the whole effect from movement in the fair value of the EBRD convertible loan is presented in profit or loss.

The fair value of the EBRD convertible loan is calculated via an internally prepared model that separately values the loan amount on a discounted cash flow basis and the conversion option using a Black-Scholes option pricing model. The market observable information assumptions used, of which the most significant is the Company's common share price, have been applied consistently to management's most likely future financing plans.

A probability weighting has been applied to each scenario, developed based on future financing plans, by using management's best estimates of the likelihood of each scenario occurring. This probability weighting was categorised as a level 3 non-market observable assumption under IFRS 13 *Fair Value Measurement* and hence results in the EBRD convertible loan valuation being a level 3 valuation.

The fair value of the EBRD convertible loan at September 30, 2023 was assessed at \$15.562 million (US\$11.527 million) (September 30, 2022: \$14.748 million or US\$10.773 million), resulted in a fair value loss of \$0.002 million recognised for the three months ended September 30, 2023 (2022: gain of \$0.145 million) and a fair value gain of \$0.006 million recognised for the nine months ended September 30, 2023 (2022: \$0.152 million).

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

9. Loans and borrowings (continued)

(b) Recognition and measurement of convertible loans (continued)

CCI convertible loan

CCI convertible loan	2023	2022
	\$000s	\$000s
Carrying amount at January 1	11,331	10,535
Adjustments recorded during the period:		
Adjustments due to the significant modification *		
Derecognition of the financial liability	(11,668)	(10,894)
Recognition of the financial liability	10,326	9,642
Transaction costs	(59)	(57)
Accrued interest	1,643	1,580
Carrying amount at September 30	11,573	10,806

^{*} Resulting from the significant modification of the CCI convertible loan, the existing financial liability was derecognised and new financial liability of \$10.326 million (2022: \$9.642 million) was recognised, while the remaining amount of that compound financial instrument of \$1.342 million (2022: \$1.252 million) was recognised as an equity

The CCI convertible loan is a compound financial instrument, whereby a liability component and an equity component were determined at initial recognition. The liability component was measured by fair valuing the convertible loan using a relevant market interest rate that would apply to an equivalent loan that does not contain an equity conversion option. The remaining amount was recognised as equity element.

The significant modification of the CCI convertible loan's conditions as per the 2023 Amendments of the CCI convertible loan resulted in recognition of newly recognised financial liability in 2023, and derecognition of both the existing financial liability and related equity component of \$1.245 million, whereby the equity component was transferred to Accumulated losses. Therefore, a new financial liability has been recognised at \$10.326 million, while the remaining amount of that compound financial instrument of \$1.342 million has been recognised as an equity component.

Similarly in 2022, due to the significant modification of the CCI convertible loan's conditions as per the 2022 Amendments of the CCI convertible loan new financial liability of \$9.642 million and equity component of \$1.252 million were recognised in 2022, while the existing financial liability and related equity component of \$1.162 million were derecognised.

Transaction costs incurred of \$0.067 million for the 2023 Amendments of the CCI convertible loan (2022: \$0.064 million incurred for the 2022 Amendments of the CCI convertible loan) were allocated on a proportional basis to the liability component of \$0.059 million (2022: \$0.057 million) and equity element of \$0.008 million (2022: \$0.007 million). Transaction costs allocated to the liability component will be fully amortised at February 28, 2024.

Subsequent to initial recognition, the liability component is measured at amortised cost by using the effective interest method.

Convertible notes

The Convertible notes are designated as FVTPL, whereby all attributable transaction costs, together with any accrued interest, foreign exchange movements and fair value adjustments are recognised in profit or loss.

During the year ended December 31, 2022 transaction costs of \$0.081 million were incurred for issuing of both convertible notes, out of which \$0.062 million were paid in 2022, \$0.054 million paid in the nine months ended September 30, 2022, while remaining \$0.019 million paid in the nine months ended September 30, 2023.

Following closing of the 2023 Private Placement (see Note 8), on January 26, 2023 both convertible notes of \$1.638 million or US\$1.25 million were converted into 35,342,120 common shares, and accordingly due to the close proximity of December 31, 2022 to their conversion, the fair value of both convertible notes at December 31, 2022 was their value of conversion, i.e. \$1.638 million, and no additional fair value adjustment on these convertible notes was recognised for the nine months ended September 30, 2023 (fair value gain of \$0.102 million recognised for the three and nine months ended September 30, 2022).

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

10. Gold purchase advance payments

On October 20, 2014 the Group entered into a Gold Purchase and Sale Agreement ("GPSA") with Royal Gold pursuant to which the Group via its wholly-owned subsidiaries agreed to sell an equivalent of 25% of future gold production from the Ilovica-Shtuka Project to Royal Gold to a maximum of 525,000 ounces and then 12.5% gold produced thereafter. In consideration, it was agreed that Royal Gold pay US\$175 million as an advance payment on the purchase price of the Ilovica-Shtuka Project's future gold production.

During 2015, under the initial tranche and part of the first anniversary payment the Group received US\$11.25 million, as part of that GPSA. All these advance payments received under the GPSA are classified as current liabilities since all conditions precedent for the third tranche were not satisfied in the agreed timetable as per GPSA.

The repayment of the advance payments is currently secured by share pledges over the Group's common shares in a number of its wholly-owned subsidiaries together with security of specific intergroup transactions and balances. On June 3, 2015 the Group obtained the concession agreement annex allowing for the exploitation concession for llovica 6 to be granted as security by way of assignment in favour to Royal Gold as well as to the Group's creditors. Royal Gold's first priority security interest will be subordinated to that of the permitted senior ranking debt finance under arrangements to be agreed with the senior financiers. Royal Gold's security interest falls away once its entire advance payment has been repaid.

Under the provisions of GPSA, in case of its termination, advance payments need to be repaid in full within 60 days of received termination notice. As at the date of these condensed consolidated interim financial statements, no termination or repayment notice has been received from Royal Gold, nor does the Group expect to receive such notice until funds for repayment of that advance payment are secured by the Group.

The following is a summary of the changes in the GPSA advance payments as at September 30, 2023 and 2022:

	2023	2022
	\$000s	\$000s
Balance on January 1	15,236	14,376
Adjustments recorded during the year:		
Foreign exchange movements:		
Unrealised foreign exchange loss	137	2,183
Currency translation reserve movements *	(185)	(1,158)
Balance on September 30	15,188	15,401

^{*}Gold purchase advance payments held within subsidiary that has Euro as functional currency

11. Related party transactions

At September 30, 2023, 46% of all issued common shares were owned by Galena Resource Equities Limited ("Galena"), an entity that is controlled by Galena Asset Management S.A., which is an affiliate of Trafigura Group Pte Ltd. ("Trafigura"). Galena has executed its right to appoint four out of eight members of the board of directors, and therefore Trafigura as ultimate controlling entity of Galena represents a controlling entity of the Company.

During the year ended December 31, 2022, the Group received US\$1.25 million (\$1.627 million) under two non-interest bearing, unsecured, convertible notes issued to Galena (see Note 9), that were converted into 35,342,120 common shares on January 26, 2023 (see Note 8).

The Group has signed an off-take agreement with Trafigura whereby the whole future production of the copper concentrate from the Ilovica-Shtuka Project will be sold to Trafigura.

Details of the transactions between the Group and other related parties are disclosed below.

Transactions with key management personnel

(a) Key management personnel transactions

The Group has the following related party:

 ARQX Capital DWC Ltd – private company owned by one of the Group's directors, as additional support for the Group's Macedonian affairs, particularly engaged in the permitting process and for the development of the Ilovica-Shtuka Project.

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

11. Related party transactions (continued)

Transactions with key management personnel (continued)

(a) Key management personnel transactions (continued)

The Group incurred the following fees and expenses in the normal course of operations in connection with related parties. Expenses have been measured at the amount which is agreed between the parties.

	Nine months ended September 30,	
	2023	2022
	\$000s	\$000s
Fees for Macedonian affairs and for support of the permitting process of the Ilovica-Shtuka Project	156	148
	156	148

At September 30, 2023, the Group owed ARQX Capital DWC Ltd \$0.017 million (December 31, 2022: \$0.035 million) for the services provided in September 2023.

(b) Key management personnel compensation

The remuneration of directors and other members of key management personnel during the nine months ended September 30, 2023 and 2022 was as follows:

	Nine months ended September 30,		
	Note	2023	2022
		\$000s	\$000s
Short-term employee benefits		247	239
Share-based payments recovery	(i)	(554)	(450)
		(307)	(211)

(i) Share-based payments expense /(recovery) is the expense/income from share options, RSUs and deferred phantom units ("DPUs") granted to directors and key management personnel.

(c) Deferred Phantom Unit Plan ("DPU Plan")

In March 2013 Euromax introduced a DPU Plan for its directors and key management personnel. Under the terms of the plan the Company's directors elected to convert their outstanding unpaid directors' fees into DPUs in lieu of a cash payment. Since 2013, directors who have elected to convert their fees into DPUs, have been making a semi-annual elections for issuing of DPUs in lieu of cash.

All DPUs granted to directors vest immediately.

However, those DPUs granted to executive officers, that contain a vesting condition relating to the Company's common share price performance compared to the Market Vectors Junior Gold Mines ETF ("GDXJ"), have a market performance vesting condition, so at grant date it is estimated that the Company's common share price performance should be at least consistent with the GDXJ's price performance. No additional DPUs were granted for the nine months ended September 30, 2023 and 2022 under this set benchmark.

All vested DPUs are revalued at the Company's reporting period end share price and only becomes payable in cash in the event that a director or key management person leaves the Group.

The total DPUs in issue at September 30, 2023 was 33,709,135 (September 30, 2022: 29,561,521). Share-based payment liabilities of \$2.191 million (December 31, 2022: \$2.749 million) are recognised as current at September 30, 2023. The DPU expense for the three months ended September 30, 2023 was \$0.084 million (2022: recovery of \$0.337 million) and DPU recovery of \$0.559 million (2022: \$0.450 million) recognised for the nine months ended September 30, 2023.

12. Contingencies and commitments

Apart of above presented contractual obligations, in other notes of these condensed consolidated interim financial statements, the Group had no further contingencies or commitments as at September 30, 2023.

Notes to the condensed consolidated interim financial statements - unaudited (Expressed in Canadian dollars, except number of common shares and per share amounts)

13. Subsequent events

No reportable events have occurred subsequent to September 30, 2023.